Roche Elecsys cardiac Troponin T-high sensitive

Faster diagnosis of acute myocardial infarction

Roche Troponin T-high sensitive (cTnT-hs)

Make a difference when every minute counts.


In the case of suspected AMI, prompt treatment is essential. Every 30 minutes of delay between symptoms and treatment increases the 1-year mortality rate by 7.5%.4

Troponin is the preferred biomarker in defining AMI according to the European Society of Cardiology (ESC) guidelines.5 In addition, it is the gold standard to distinguish between AMI and non-AMI patients.5,6

Roche Elecsys cardiac Troponin T-high sensitive (TnT-hs) can reduce the time needed to rule-in or rule-out NSTEMI to as little as just 1 hour.1-3



Do you have any questions?
Contact Us


 Early and effective diagnosis with Roche  Elecsys cardiac Troponin T-high sensitive7-9


As supported by the use of the 0/1 hour rule-in and rule-out algorithm recommended by international guidelines5


Safely reduce time to diagnosis

  • Triage over 75% of patients within 1 hour as validated by three multicentre studies with over 3,000 patients7-9
  • Safely rule-out AMI and confidently discharge patients based on a high negative predictive value (99.1% - 100%) and low 30 day mortality rate (0.0% - 0.2%)7-9
In-hospital management

Lower the need for cardiac stress testing

  • Significantly reduce the need for cardiac stress testing by exercise electrocardiogram (ECG)10


Disease monitoring

Shorten stays in the emergency department (ED)

  • Facilitate early discharge or transfer from the ED by reducing time spent in ED by 2.1 hours (33%) vs standard practice11
Download the PDF to learn more about how Roche Elecsys cardiac Troponin T-high sensitive can help support your clinical decisions.
Download PDF
Roche Troponin T-high sensitive (TnT-hs)

Assay specifications

  • Assay time

    9 minute STAT 18 minutes routine assay

  • 99th percentile upper reference limit

    14 ng/L (pg/mL)

  • 10% CV precision

    13 ng/L (pg/mL)

  • Sample material

    Heparin, EDTA plasma and serum


NSTEMI: non–ST-segment elevation myocardial infarction



  1. Bandstein et al. (2014). J Am Coll Cardiol 63, 2569-2578
  2. Body et al. (2015). Clin Chem 61, 983-989
  3. Rubini-Giménezet al. (2013). Int J Cardiol 168, 3896-3901
  4. De Luca et al. (2004). Circulation 109, 1223-1225
  5. Roffi et al. (2016). Eur Heart J 37, 267-315
  6. Neumann et al. (2017). PLoS One 12:e0174288
  7. Reichlin et al. (2012). Arch Intern Med 172, 1211-1218
  8. Reichlin et al. (2015). CMAJ 187, E243-E252
  9. Mueller et al. (2016). Annal Emerg Med 68, 76-87
  10. Twerenbold et al. (2016). Eur Heart J 37, 3324-3332
  11. Ambavane et al. (2017). PLoS One 12, e0187662